Clinical Trial Update: Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer

View source ↗

Summary

This clinical study investigates real-world dosing of PARP inhibitors in patients over 70 with advanced ovarian cancer. Recruitment is currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• PARP inhibitors (class) (PARP inhibitor)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Ovarian Cancer | Status: RECRUITING